INS and type 1 diabetes mellitus: For example, Kuhadiya et al. reported that the addition of 1.2 and 1.8 mg of Liraglutide in T1DM patients over 12 weeks is associated with a reduction of post-prandial plasma glucagon concentration (72 ± 12% and 47 ± 12%, respectively (p < 0.05)), significant weight loss, and a decrease in their insulin requirements [127].